Vaxart (STU:NB11) ROE % Adjusted to Book Value: 12.88% (As of Mar. 2026)

Vaxart STU:NB11 63 ROE % Adjusted to Book Value is 12.88% as of Mar. 2026. GuruFocus rates STU:NB11 with a GF Score™ of 63/100 and a GF Value™ of €8.82. The stock has 3 warning signs investors should review.

Vaxart's ROE % for the quarter that ended in Mar. 2026 was 22.92%. Vaxart's PB Ratio for the quarter that ended in Mar. 2026 was 1.78. Vaxart's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 12.88%.

Vaxart ROE % Adjusted to Book Value Related Terms

Vaxart ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Vaxart's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vaxart ROE % Adjusted to Book Value Chart

Vaxart Annual Data

Trend

Jun16

Jun17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-11.11

-64.87

-65.36

-42.86

23.61

Vaxart Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-57.44	-45.94	-36.05	427.36	12.88

STU:NB11 vs SPRO, ADCT, GNLX: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Vaxart's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vaxart ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxart's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Vaxart's ROE % Adjusted to Book Value falls into.

Save Embed

63GF Score

Vaxart Inc STU:NB11

ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Vaxart ROE % Adjusted to Book Value Calculation

Vaxart's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	21.25%	/	0.90
	=	23.61%

Vaxart's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	22.92%	/	1.78
	=	12.88%

Frequently Asked Questions Learn more about ROE % Adjusted to Book Value →

What does a ROE % Adjusted to Book Value of 12.88% mean?

Vaxart (STU:NB11) has a ROE % Adjusted to Book Value of 12.88% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Vaxart and its competitors.

Is Vaxart's ROE % Adjusted to Book Value too high?

Vaxart's current ROE % Adjusted to Book Value is 12.88%. Overall, Vaxart has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.

How does Vaxart's ROE % Adjusted to Book Value compare to SPRO and ADCT?

Vaxart's ROE % Adjusted to Book Value of 12.88% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROE % Adjusted to Book Value for a Biotechnology company?

A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROE % Adjusted to Book Value mean?

A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Vaxart and its competitors. Vaxart's current ROE % Adjusted to Book Value is 12.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Vaxart stock overvalued right now?

Vaxart (STU:NB11) has a current ROE % Adjusted to Book Value of 12.88%. The stock's GF Value™ is €8.82, compared to a current price of €0.60 — trading 93.2% below its estimated fair value. The current ROE % Adjusted to Book Value is 12.88%. Vaxart's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROE % Adjusted to Book Value calculated?

ROE % Adjusted to Book Value is calculated from a company's financial statements. For Vaxart (STU:NB11), the current ROE % Adjusted to Book Value is 12.88% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vaxart (STU:NB11) Overvalued in 2026?

Based on GuruFocus' analysis, Vaxart stock appears to be undervalued. The current stock price of €0.60 is trading 93.2% below its estimated GF Value™ of €8.82.

Key valuation signals for STU:NB11:

ROE % Adjusted to Book Value: 12.88%
GF Value™: €8.82 vs. price of €0.60 (93.2% below fair value)
GF Score™: 63/100 with 3 warning signs

No single metric tells the full story. See the STU:NB11 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vaxart Business Description

Industry Healthcare Biotechnology

Comparable Companies SPRO ADCT GNLX COYA AGEN VTVT LIXT SMNR CNTB ENLV VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges VXRT:USA

Address 170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080

Website https://www.vaxart.com

Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically, all the business activity functions through the region of the United States.

63GF Score

Get the complete analysis for STU:NB11

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.60

Price

€8.82

GF Value

View STU:NB11 Analysis

See ROE % Adjusted to Book Value data for all stocks →